Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
vvDD-hIL2-2-RG-1 in metastatic GI and peritoneal tumors
NCT07001592Phase 1Recruiting
- Sponsor
- Allegheny Singer Research Institute
- Start
- May 2025
- Primary completion
- Apr 2028
- Modality
- Oncolytic Viruses, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vvDD-hIL-2-RG-1 in gastrointestinal cancer, sponsored by Allegheny Singer Research Institute. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 28 days, Maximally-tolerated dose at 28 days and 1 more. Started May 2025; status: recruiting.
02
Drugs
vvDD-hIL-2-RG-1
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT07001592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001592.